Earning Analysis
Welcome to our in-depth analysis of Cellectis SA(CLLS) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Cellectis SA earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency:
Actual
Estimate
Surprise Analysis
| FY2025Q3 | 2025-11-07 | After Hours | - | - | - | 9.55M | 37.12M | +288.62 | +11.29 | +11.91 |
| FY2029Q1 | 2025-08-04 | After Hours | -0.24 | -0.22 | +9.84 | 11.64M | 18.19M | +56.23 | -16.23 | -13.91 |
| FY2028Q4 | 2025-05-12 | After Hours | -0.23 | -0.18 | +21.74 | 13.83M | 12.00M | -13.27 | -6.62 | +4.64 |
| FY2028Q3 | 2025-03-13 | After Hours | 0.06 | - | - | 9.59M | 33.18M | +245.92 | -3.88 | -1.55 |
| FY2028Q2 | 2024-11-04 | After Hours | -0.20 | - | - | 9.10M | 18.03M | +98.18 | +1.14 | +8.52 |
| FY2028Q1 | 2024-08-06 | - | -0.33 | -0.28 | +15.15 | 3.73M | 9.50M | +154.72 | +1.47 | - |
| FY2027Q4 | 2024-05-28 | - | - | -0.15 | - | 3.41M | 6.49M | +90.08 | -1.42 | -6.03 |
| FY2027Q3 | 2024-04-29 | - | - | -0.64 | - | 16.12M | 1.99M | -87.65 | +2.15 | +19.31 |
| FY2027Q2 | 2023-11-06 | - | -0.36 | -0.31 | +13.89 | 3.72M | 1.64M | -55.93 | -3.50 | -12.24 |
| FY2027Q1 | 2023-08-03 | - | -0.38 | -0.14 | +63.16 | 4.62M | 2.00M | -56.74 | +1.56 | -4.69 |
CLLS Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Cellectis SA reported performance for FY2025Q3, announced on 2025-11-07. The company achieved an EPS of , compared to analyst estimates of by % . Revenue for the quarter reached 37.12M compared to expectations of 9.55M by 288.62% .
The stock price reacted with a 11.29% one-day change and a 11.91% five-day change following the earnings release. These movements reflect market reaction in Cellectis SA growth trajectory and strategic initiatives.
CLLS Earnings Forecast
Looking ahead, Cellectis SA(CLLS) remains a focal point for investors seeking growth opportunities. Analyst forecasts for project quarter revenue of and an EPS of .
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been No Change by 0%, while EPS estimates have been No Change by -0%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Upward by 20.74% . These revisions correlate with a 80.22% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Cellectis SA long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between CLLS's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Revenue Estimates for Q4 2025
Revise Upward
+20.74%
In Past 3 Month
Stock Price
Go Up
+80.22%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:45.85M
--
EPS Estimate-Annual FY 2025:-0.77
—
Stock Price4.83
CLLS Revenue and EPS Performance: A Historical Perspective
Cellectis SA revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q3 (2025-11-07,After Hours):
EPS: (Actual) vs. (Estimate) (%)
Revenue: 37.12M (Actual) vs. 9.55M (Estimate) (288.62%)
Price Reaction: 11.29%(1-Day), 11.91%(5-Day)
FY2029Q1 (2025-08-04,After Hours):
EPS: -0.22 (Actual) vs.-0.24 (Estimate) (9.84%)
Revenue: 18.19M (Actual) vs. 11.64M (Estimate) (56.23%)
Price Reaction: -16.23%(1-Day), -13.91%(5-Day)
FY2028Q4 (2025-05-12,After Hours):
EPS: -0.18 (Actual) vs.-0.23 (Estimate) (21.74%)
Revenue: 12.00M (Actual) vs. 13.83M (Estimate) (-13.27%)
Price Reaction: -6.62%(1-Day), 4.64%(5-Day)
Earnings Reaction
The chart below shows how CLLS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CLLS sees a -3.79% change in stock price 10 days leading up to the earnings, and a +7.53% change 10 days following the report. On the earnings day itself, the stock moves by -0.28%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed 11.29% on the day following the earnings release and then changed by 47.02% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Cellectis SA (CLLS) Q2 2025 Earnings Call Summary
Neutral
2025-08-05
The earnings call summary presents a mixed picture. Financials show a cash decrease, but the cash runway is secure until 2027. Product development updates are promising, with regulatory alignment and no barriers to Phase II trials. However, uncertainties remain, such as the Servier arbitration decision and lack of milestone payment details. The Q&A session did not reveal major negative sentiments but highlighted cautious optimism from management. The overall sentiment is neutral, as positive product development is offset by financial and legal uncertainties.
Cellectis SA (CLLS) Q4 2024 Earnings Call Summary
Positive
2025-03-14
The earnings call reveals a strong financial position with significant investments from AstraZeneca and stable cash reserves. The Q&A section highlights confidence in upcoming data releases, suggesting positive future developments. The collaboration with AstraZeneca is fully reimbursed, reducing cash burn. Despite competitive pressures and supply chain challenges, the overall sentiment leans positive due to strategic partnerships and financial strength.
Cellectis S.A. (CLLS) Q3 2024 Earnings Call Summary
Neutral
2024-11-05
The earnings call presents mixed signals. The AstraZeneca collaboration and strong cash position are positive indicators, but supply chain challenges and intense competition in cell and gene therapy pose risks. The Q&A reveals management's cautious approach to prioritizing projects and lack of clarity on future datasets. Additionally, deprioritizing UCART123 raises concerns. Despite these issues, the partnership with AstraZeneca provides a financial buffer, mitigating some negative impacts. Overall, the sentiment is neutral as positives balance out the negatives.
People Also Watch
FAQ
What were the key highlights of CLLS’s latest earnings report for FY2025Q3?
How did CLLS’s stock price react after the FY2025Q3 earnings release?
What are the revenue and EPS estimates for CLLS for undefined?
How does CLLS’s stock price correlate with earnings forecast revisions?
What should investors expect from CLLS’s next earnings report?